Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2007
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XE07
|
| gptkbp:bioavailability |
<1%
|
| gptkbp:brand |
Tykerb
Tyverb |
| gptkbp:CASNumber |
231277-92-2
|
| gptkbp:chemicalFormula |
C29H26ClFN4O4S
|
| gptkbp:combines |
gptkb:capecitabine
gptkb:letrozole |
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
24 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lapatinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:metabolism |
gptkb:CYP3A5
gptkb:CYP3A4 |
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hand-foot_syndrome
nausea diarrhea fatigue rash |
| gptkbp:target |
gptkb:EGFR
gptkb:HER2_receptor |
| gptkbp:usedFor |
gptkb:cancer
gptkb:HER2-positive_breast_cancer |
| gptkbp:bfsParent |
gptkb:NCT00239681
|
| gptkbp:bfsLayer |
7
|